News and Events, Recent News

BriaCell Initiates Dosing in Phase I/IIa Combination Study with KEYTRUDA® or YERVOY®

· Patient dosing is underway in a combination study of Bria-IMT™ with KEYTRUDA® (by Merck & Co., Inc.) or YERVOY® (by Bristol-Myers Squibb Company) in advanced breast cancer. · KEYTRUDA® and YERVOY® have been highly recognized for their potent immune boosting properties – Nobel Prize in Medicine 2018 – validating BriaCell’s strategy to use these […]